Commonwealth Equity Services LLC Buys 3,363 Shares of McKesson Corporation $MCK

Commonwealth Equity Services LLC increased its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 7.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,169 shares of the company's stock after purchasing an additional 3,363 shares during the quarter. Commonwealth Equity Services LLC's holdings in McKesson were worth $41,981,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MCK. BlackRock Inc. acquired a new stake in McKesson in the 2nd quarter valued at about $8,156,743,000. Bank of America Corp DE purchased a new position in shares of McKesson in the 2nd quarter valued at about $998,896,000. Legal & General Group Plc acquired a new position in shares of McKesson during the second quarter worth about $656,566,000. The Manufacturers Life Insurance Company acquired a new position in shares of McKesson during the second quarter worth about $651,462,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of McKesson during the second quarter worth approximately $599,060,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Price Performance

Shares of NYSE MCK opened at $1,060.79 on Friday. The company has a market capitalization of $122.48 billion, a price-to-earnings ratio of 27.28, a price-to-earnings-growth ratio of 2.08 and a beta of 0.27. The business has a 50-day moving average of $938.13 and a two-hundred day moving average of $868.12. McKesson Corporation has a 1 year low of $723.68 and a 1 year high of $1,121.50.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.72 by $0.96. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The business had revenue of $110.96 billion during the quarter, compared to analysts' expectations of $109.90 billion. During the same period in the prior year, the firm posted $9.86 EPS. The business's quarterly revenue was up 7.5% compared to the same quarter last year. As a group, equities research analysts expect that McKesson Corporation will post 46.21 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 annualized dividend and a yield of 0.4%. McKesson's payout ratio is presently 9.67%.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Robert W. Baird set a $1,015.00 target price on shares of McKesson in a report on Thursday, August 6th. Weiss Ratings upgraded shares of McKesson from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, September 4th. Wall Street Zen upgraded shares of McKesson from a "hold" rating to a "buy" rating in a report on Saturday, October 17th. Wells Fargo & Company increased their price objective on shares of McKesson from $812.00 to $933.00 and gave the company an "equal weight" rating in a research report on Tuesday, August 11th. Finally, Leerink Partners raised their price objective on shares of McKesson from $1,070.00 to $1,200.00 and gave the company an "outperform" rating in a report on Thursday. Fifteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, McKesson currently has a consensus rating of "Moderate Buy" and an average price target of $1,026.18.

Insider Buying and Selling

In related news, Director Bradley Lerman sold 301 shares of the company's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Francisco Fraga sold 650 shares of the stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total transaction of $716,924.00. Following the completion of the transaction, the executive vice president owned 4,414 shares in the company, valued at $4,868,465.44. This represents a 12.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,462 shares of company stock worth $2,511,106 over the last 90 days. 0.06% of the stock is owned by insiders.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.